Effect of Superior Laryngeal Nerve Block for Neurogenic Cough: A Single-Arm Meta-Analysis.

Authors

Thamiris D D Cabral, Renata M Knoll, Bruno D V Vendramini, Jaime Plane, João Evangelista P Conrado, Matthew R Naunheim

Published in

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. Jun 19, 2026. Epub Jun 19, 2026.

Abstract

We aimed to assess cough symptom improvement following superior laryngeal nerve block (SLNB) in patients with neurogenic cough (NC).
Studies were systematically searched on PubMed, Embase, Web of Science, and Cochrane Library.
Articles reporting SLNB for the treatment of NC were included. Outcomes of interest included subjective reporting of improvement, patient-reported outcome measures, and adverse events. Mean difference (MD) was used for continuous outcomes and proportions for binary endpoints, with 95% confidence intervals (CI).
Eight retrospective studies involving 552 patients met inclusion criteria. The pooled proportion of subjective improvement of cough following SLNB was 74.04% (95% CI 68.61-78.81, I² = 13.6%). Patients experienced a statistically significant reduction in Cough Severity Index scores (MD -7.37, 95% CI -13.42 to -1.32, P = .02, I² = 81.7%), with the greatest reduction in those who underwent 3 or more injections (MD -10.57, 95% CI -19.37 to -1.78, I² = 33.4%, P = .02). Adverse events were minimal and self-resolving, with 17.91% and 3.35% of patients experiencing local transient and systemic transient events, respectively. Injection-limiting/serious adverse events were rare, occurring in 1.97% of patients.
Our findings suggest that SLNB may benefit a substantial number of patients, as evidenced by improvements in both subjective reports and cough-specific patient-reported outcomes, while maintaining a favorable safety profile with minimal adverse events. Additionally, patients who received multiple injections generally experienced greater reductions in cough severity. Further large-scale clinical trials are needed to confirm the efficacy and long-term effects of this treatment modality.
II.

PMID:
42319377
Bibliographic data and abstract were imported from PubMed on 19 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.